A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD.

Kristen L NowakRahul KakkarMatt DevalarajaLarry LoWansu ParkJoga GobburuDouglas KlingMichael DavidsonMichel Chonchol

Published in: Kidney360 (2020)

In adults with moderate-to-severe CKD and evidence of chronic inflammation, a single-injection of the IL-6 inhibitor ziltivekimab was safe and highly effective at suppressing hsCRP over 12 weeks.

Keyphrases

monoclonal antibody
chronic kidney disease
open label
endothelial cells
oxidative stress
double blind
signaling pathway
phase iii
high intensity
early onset
randomized controlled trial
phase ii
study protocol